MC
LCTX icon

Moors & Cabot’s Lineage Cell Therapeutics LCTX Stock Holding History

Moors & Cabot’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,400
Closed -$18.6K – 886
2023
Q1 		$18.6K Hold
12,400
– – ﹤0.01% 832
2022
Q4 		$14.5K Hold
12,400
– – ﹤0.01% 827
2022
Q3 		$14K Hold
12,400
– – ﹤0.01% 806
2022
Q2 		$20K Hold
12,400
– – ﹤0.01% 786
2022
Q1 		$19K Hold
12,400
– – ﹤0.01% 851
2021
Q4 		$30K Sell
12,400
-6,000
-33% -$14K ﹤0.01% 849
2021
Q3 		$47K Sell
18,400
-4,960
-21% -$12.7K ﹤0.01% 820
2021
Q2 		$67K Buy
23,360
+3,690
+19% +$9.55K ﹤0.01% 784
2021
Q1 		$46K Buy
19,670
+3,920
+25% +$9.41K ﹤0.01% 745
2020
Q4 		$27K Buy
15,750
+1,000
+7% +$1.4K ﹤0.01% 718
2020
Q3 		$14K Sell
14,750
-1,400
-9% -$1.24K ﹤0.01% 683
2020
Q2 		$14K Sell
16,150
-4,000
-20% -$3.52K ﹤0.01% 650
2020
Q1 		$15K Hold
20,150
– – ﹤0.01% 577
2019
Q4 		$18K Sell
20,150
-15,000
-43% -$12.5K ﹤0.01% 601
2019
Q3 		$34K Sell
35,150
-3,000
-8% -$3.11K ﹤0.01% 613
2019
Q2 		$41K Buy
38,150
+9,000
+31% +$10.4K 0.01% 540
2019
Q1 		$38K Buy
29,150
+3,000
+11% +$3.73K 0.01% 515
2018
Q4 		$25K Sell
26,150
-28,428
-52% -$43.5K ﹤0.01% 497
2018
Q3 		$111K Buy
54,578
+1,943
+4% +$4.08K 0.01% 560
2018
Q2 		$94K Sell
52,635
-7,292
-12% -$14.7K 0.01% 540
2018
Q1 		$141K Buy
59,927
+7,178
+14% +$16.8K 0.02% 549
2017
Q4 		$99K Sell
52,749
-1,006
-2% -$2.2K 0.01% 545
2017
Q3 		$135K Sell
53,755
-2,972
-5% -$7.37K 0.02% 514
2017
Q2 		$154K Buy
56,727
+11,430
+25% +$31.9K 0.03% 483
2017
Q1 		$134K Buy
45,297
+6,058
+15% +$17.2K 0.02% 483
2016
Q4 		$124K Buy
39,239
+26,666
+212% +$81.9K 0.02% 508
2016
Q3 		$44K Buy
+12,573
New +$34.7K 0.01% 530

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Moors & Cabot's LCTX Position: Q2 2023 in Review

Moors & Cabot sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 12,400 shares — an estimated $18.6K sold.

Moors & Cabot first reported a position in LCTX in Q3 2016 and held it in 27 quarters. The position peaked at $154K in Q2 2017. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

  • Moors & Cabot reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Moors & Cabot sold 12,400 Lineage Cell Therapeutics shares in Q2 2023, an estimated $18.6K.
  • Moors & Cabot first reported a position in Lineage Cell Therapeutics in Q3 2016 and held it in 27 quarters.
  • Moors & Cabot's Lineage Cell Therapeutics position peaked at $154K in Q2 2017.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on Moors & Cabot's 13F filing for Q2 2023, filed 10 Aug 2023.